

## Xymedon conjugate with biogenic acids. Antioxidant properties of a conjugate of Xymedon with L-ascorbic acid \*

A. B. Vyshtakalyuk,<sup>a\*</sup> V. E. Semenov,<sup>a,b</sup> I. A. Sudakov,<sup>b</sup> K. N. Bushmeleva,<sup>b</sup> L. F. Gumarova,<sup>a</sup>  
A. A. Parfenov,<sup>a,b</sup> N. G. Nazarov,<sup>a,c</sup> I. V. Galyametdinova,<sup>a</sup> and V. V. Zobov<sup>a,c</sup>

<sup>a</sup>A. E. Arbuzov Institute of Organic and Physical Chemistry, Kazan Scientific Center, Russian Academy of Sciences,  
8 ul. Acad. Arbuzova, 420088 Kazan, Russian Federation

Fax: +7 (843) 273 1872. E-mail: alex.vysh@mail.ru


<sup>b</sup>Kazan National Research Technological University,  
68 ul. K. Marksa, 420015 Kazan, Russian Federation.

<sup>c</sup>Kazan Federal University,  
5 ul. Tovarishcheskaya, 420097 Kazan, Russian Federation

Antiradical activity and antioxidant properties of a conjugate of Xymedon with L-ascorbic acid were studied. In contrast to Xymedon, a conjugate of Xymedon with L-ascorbic acid was found to react with free radicals. Pro-oxidant activity of the conjugate of Xymedon with L-ascorbic acid in a chemiluminescence system is weaker as compared to individual L-ascorbic acid. This is the evidence of the increase in the stability of ascorbic acid upon conjugation with a molecule of Xymedon. Conjugate of Xymedon with L-ascorbic acid facilitates the decrease in the concentration of a lipid peroxidation product (malondialdehyde) and the activity of superoxide dismutase in liver and serum of laboratory animals exposed to intoxication with a known hepatotropic toxin CCl<sub>4</sub>. This observation shows the contribution of the antioxidant action to the hepatoprotective effect of the studied Xymedon derivative.

**Key words:** pyrimidines, antiradical activity, toxic liver injury, ascorbic acid, antioxidant activity.


Pyrimidine derivatives attract attention due to their ability to stimulate tissue regeneration. Among them, Xymedon (1-(2-hydroxyethyl)-4,6-dimethyl-1,2-dihydropyrimidine-2-one) is a known medicine with considerable regenerative and reparative properties,<sup>1</sup> which is successfully used in clinical practice for treatment of burn wounds and other pathological states, as well as in the post-operative period.<sup>2–5</sup> In our earlier studies,<sup>6,7</sup> we revealed hepatoprotective activity of Xymedon, and, in particular, the decrease in pathomorphological changes in liver and normalization of biochemical markers of liver disease.



Xymedon

In recent publications,<sup>8–10</sup> chemical modification of therapeutic drugs, and conjugation in particular, is re-

garded as a way to increase their bioavailability and efficiency. Earlier, in our publication<sup>11</sup> we reported the synthesis of Xymedon complexes **1a–e** with biogenic acids, namely, succinic, ascorbic, *p*-aminobenzoic, nicotinic, and L-2-amino-4-(methylthio)butanoic (L-methionine) acids.



These biogenic acids were chosen for preparation of Xymedon complexes **1a–e** since they are common me-

\* Based on the materials of III Interdisciplinary Symposium on Medicinal, Organic, and Biological Chemistry and Pharmaceuticals (MOBI-ChemPharma-2017; 28–31 May, 2017; Sevastopol, Russia).